089140 — NexturnBioScience Co Income Statement

0.000.00%

Last trade - 00:00

IndustrialsHighly SpeculativeMicro CapSucker Stock

Market Cap
KR₩36bn
Enterprise Value
KR₩81bn
Revenue
KR₩32bn

Annual income statement for NexturnBioScience Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	R2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	9,685	16,972	23,463	41,258	31,640
Cost of Revenue
Gross Profit	2,168	4,818	5,447	9,218	6,840
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	12,703	19,362	27,695	55,843	53,073
Operating Profit	-3,018	-2,390	-4,232	-14,586	-21,433
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-3,430	-3,997	-4,639	16,923	-14,432
Provision for Income Taxes
Net Income After Taxes	-2,436	-4,433	-4,879	9,275	-13,005
Net Income Before Extraordinary Items
Extraordinary Items
Net Income	-2,436	-4,433	-4,688	9,681	-13,005
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income	-2,436	-4,433	-4,688	8,931	-13,005
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-380	-694	-659	1,703	7.68
Dividends per Share